Scynexis (SCYX) Non Operating Income (2013 - 2026)
Scynexis' (SCYX) quarterly Non Operating Income came in at $15.2 million in Q2 2026, up 466.97% on a YoY basis from $2.7 million in Q2 2025, and up 447.98% quarter-over-quarter from -$4.4 million in Q1 2026.
Analysis
Scynexis (SCYX) Non Operating Income (2013 - 2026) Analysis & Trends
Scynexis (SCYX) has reported Non Operating Income for 14 consecutive years, with $15.2 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Non Operating Income rose 466.97% year-over-year to $15.2 million; the trailing twelve-month figure through Jun 2026 stood at $12.4 million (down 25.77% YoY), and the FY2025 full-year result was $7.5 million, down 53.29% from the prior year.
- Non Operating Income rose to $15.2 million in Q2 2026 per SCYX's latest filing, from -$4.4 million in the prior quarter.
- Across five years, Non Operating Income topped out at $15.2 million in Q2 2026 and bottomed at -$23.2 million in Q1 2023.
- Historically, Non Operating Income has averaged $2.6 million across 5 years, with a median of $3.6 million in 2023.
- The sharpest annual moves came in 2022 and 2023: Non Operating Income surged 583.7% in 2022, then tumbled 341.93% in 2023.
- Over 5 years, Non Operating Income stood at $8.1 million in 2022, then plunged by 55.08% to $3.6 million in 2023, then grew by 0.72% to $3.6 million in 2024, then slumped by 52.32% to $1.7 million in 2025, then jumped by 773.46% to $15.2 million in 2026.
- According to Business Quant data, Non Operating Income over the past three periods registered $15.2 million, -$4.4 million, and $1.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | -73.00 Mn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | 387.00 Mn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 234.30 Mn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | - |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | -53.64 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | - |
| 10 | Scynexis | 58.41 Mn | -56.29 Mn | - | 15.17 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 15.17 Mn |
| Mar 31, 2026 | -4.36 Mn |
| Dec 31, 2025 | 1.74 Mn |
| Sep 30, 2025 | -186,000.00 |
| Jun 30, 2025 | 2.68 Mn |
| Mar 31, 2025 | 3.22 Mn |
| Dec 31, 2024 | 3.64 Mn |
| Sep 30, 2024 | 7.12 Mn |
| Jun 30, 2024 | -5.22 Mn |
| Mar 31, 2024 | 10.45 Mn |
| Dec 31, 2023 | 3.62 Mn |
| Sep 30, 2023 | 8.34 Mn |
| Jun 30, 2023 | 5.75 Mn |
| Mar 31, 2023 | -23.19 Mn |
| Dec 31, 2022 | 8.05 Mn |
| Sep 30, 2022 | -7.78 Mn |
| Jun 30, 2022 | 8.39 Mn |
| Mar 31, 2022 | 9.59 Mn |
| Dec 31, 2021 | -6.95 Mn |
| Sep 30, 2021 | 18.79 Mn |